Get the Stockscreener App
31.13
6.50%
1.90
After Hours:
31.13
Dyne Therapeutics Inc stock is traded at $31.13, with a volume of 1.40M.
It is up +6.50% in the last 24 hours and up +1.30% over the past month.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
See More
Previous Close:
$29.23
Open:
$29.62
24h Volume:
1.40M
Relative Volume:
1.10
Market Cap:
$2.97B
Revenue:
-
Net Income/Loss:
$-257.60M
P/E Ratio:
-9.1559
EPS:
-3.4
Net Cash Flow:
$-220.31M
1W Performance:
+3.80%
1M Performance:
+1.30%
6M Performance:
-0.29%
1Y Performance:
+192.03%
1-Day Range:
$28.80
$31.32
1-Week Range:
$28.60
$31.32
52-Week Range:
$10.12
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
31.13 | 2.97B | 0 | -257.60M | -220.31M | -3.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Connor Clark & Lunn Investment Management Ltd. Invests $1.48 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne, Avidity initiated at outperform by RBC on DM1 drugs (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
RBC Capital starts Dyne Therapeutics shares at Outperform, targets genetic medicine success - Investing.com UK
Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Jennison Associates LLC Has $48.38 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
DYN (Dyne Therapeutics) 9-Day RSI : 49.47 (As of Nov. 21, 2024) - GuruFocus.com
Dyne Therapeutics director Incerti Carlo sells $474,045 in stock - Investing.com India
State of New Jersey Common Pension Fund D Invests $1.59 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics director Incerti Carlo sells $474,045 in stock By Investing.com - Investing.com Canada
Dyne therapeutics director Jason Rhodes sells $25,884 in stock - Investing.com
Dyne therapeutics director Jason Rhodes sells $25,884 in stock By Investing.com - Investing.com Canada
Dyne therapeutics chief scientific officer sells shares worth $80,539 - Investing.com
Dyne Therapeutics SVP sells $77,127 in stock - Investing.com India
Dyne therapeutics chief scientific officer sells shares worth $80,539 By Investing.com - Investing.com UK
Dyne Therapeutics SVP sells $77,127 in stock By Investing.com - Investing.com UK
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by US Bancorp DE - Defense World
FY2024 EPS Estimate for Dyne Therapeutics Lowered by Analyst - MarketBeat
FY2024 EPS Forecast for Dyne Therapeutics Lowered by Analyst - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 9.1% in October - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1%Time to Sell? - MarketBeat
RA Capital Management, L.P. Expands Stake in Dyne Therapeutics I - GuruFocus.com
Citadel Advisors LLC Adjusts Stake in Dyne Therapeutics Inc - GuruFocus.com
Janus Henderson Group PLC's Strategic Acquisition in Dyne Therap - GuruFocus.com
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownTime to Sell? - MarketBeat
Deep Track Capital, LP Reduces Stake in Dyne Therapeutics Inc - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Dyne Therapeutics Inc - GuruFocus.com
Dyne Therapeutics Reveals Q3 Results and Trial Updates - TipRanks
Dyne Therapeutics (NASDAQ:DYN) Given Buy Rating at HC Wainwright - MarketBeat
FMR LLC Bolsters Position in Dyne Therapeutics Inc with Signific - GuruFocus.com
Dyne Therapeutics Inc Reports Q3 2024 EPS of -$0.96, Missing Est - GuruFocus.com
Dyne Therapeutics Inc (DYN) Quarterly 10-Q Report - Quartzy
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Dyne Therapeutics' DMD Drug Shows Promise; $723.7M Cash Position Fuels Clinical Progress | DYN Stock News - StockTitan
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely - Simply Wall St
Lisanti Capital Growth LLC Has $622,000 Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.60 Average Price Target from Brokerages - MarketBeat
Creative Planning Has $381,000 Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Dyne Therapeutics to Present at Three Major Healthcare Investor Conferences | DYN Stock News - StockTitan
Dyne Therapeutics Enters Oversold Territory (DYN) - Nasdaq
Vanguard Group Inc's Strategic Acquisition in Dyne Therapeutics Inc - GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
How the (DYN) price action is used to our Advantage - Stock Traders Daily
Dyne Therapeutics (DYN) Stock Dips Amidst Financial Report Insig - GuruFocus.com
Dyne cut to neutral by J.P. Morgan on stock's outperformance (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (NASDAQ:DYN) Downgraded by JPMorgan Chase & Co. to "Neutral" - MarketBeat
Dyne Therapeutics director Kersten Dirk sells shares totaling $475,878 - Investing.com India
Dyne Therapeutics director Kersten Dirk sells shares totaling $475,878 By Investing.com - Investing.com South Africa
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):